This RARE edition features Ulf Staginnus, a seasoned expert in Market Access and Pricing, who unpacks what it really takes for biotechs to succeed in Europe. Drawing on nearly 30 years of experience, Ulf discusses the future of HTA, payer negotiation strategies, and the shifting policy environment shaping access to orphan and precision medicines.
How we partner with life sciences organisations to build the teams behind their growth.
SciPro partnered with TetraScience to support the rapid global expansion of its SciBorg organisation, delivering 13 specialist technical hires across the UK, US, Germany and Austria within six months to help scale its Scientific Data and AI platform.
SciPro partnered with Sera Medicines and its portfolio companies to deliver specialist leadership and technical talent, supporting more than 30 strategic searches and helping scale innovative biotech businesses from early growth through to commercial expansion.
SciPro partnered with Valo Health to deliver specialist AI, data science and research talent, successfully placing six highly specialised professionals to support the company's AI-driven drug discovery platform.
SciPro partnered with Pyxis Oncology for four years, delivering 17 specialist hires across executive leadership, clinical development and scientific functions to support the growth of its oncology pipeline.
Pfizer is a multinational pharmaceutical and biotechnology corporation. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
Brainomix specialises in the creation of AI-powered imaging biomarkers that enable precision medicine for better treatment decisions.
Bristol Myers Squibb (BMS) is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
